NCT06721598View on ClinicalTrials.gov

An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders

Not yet recruitingOBSERVATIONAL

Enrollment

60

Participants

Timeline

Start Date

January 9, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions

Non-Hodgkin Lymphoma, B-cellAcute Lymphoblastic Leukemia ALL

Trial Locations (1)

125167

National Medical Research Center for Hematology, Moscow

All Listed Sponsors

lead

National Research Center for Hematology, Russia

NETWORK